Amid a contentious political environment, consumer pharmaceutical firm Kenvue Inc (NYSE:KVUE) finds itself under a harsh spotlight. Specifically, its popular drug Tylenol has attracted the ire of the White House. Late last month, President Donald Trump stated on Truth Social that pregnant women shouldn't use Tylenol unless absolutely necessary. With Kenvue courting unwanted attention, KVUE stock has suffered badly. Still, there could be an opportunity for contrarian traders.
Fundamentally, this latest controversy isn't the first rodeo for the brand. True, technically speaking, Kenvue is a young enterprise, which was spun off from pharmaceutical giant Johnson & Johnson (NYSE:JNJ). However, as The New York Times detailed, Tylenol — which goes by the generic name acetaminophen — has previously faced severe crises. At the time, Johnson & Johnson was able to restore public trust.
